Brentwood, Tenn. - April 9, 2009 - Praxis, a company specializing in centralized patient recruitment for clinical research studies, will partner with a successful Biotech company to provide strategic patient recruitment services for a nation wide study involving a serious heart condition.
This trial seeks to test study drug effectiveness in patients with heart failure. “There are several key strategic measures that need to be taken in a study of this nature. Recognizing that the older patient population will, in most cases, be supported by some family member(s) it will be key that our strategic messaging talk to both parties simultaneously to help keep budgets under control for the sponsor.” Donna Beasley, VP of Operations with Praxis also adds, “There are roughly 3.5 million people in the U.S. that suffer from this serious condition. A major point of significance here is when you look outside the U.S. For example, in Europe there are approximately 14 million that suffer from heart failure. This drug stands to bring benefit to this patient population all over the world.”
Praxis will be providing strategy on all fronts including protocol & study feasibility as well as site selection guidance and positioning. Praxis will also be providing full service recruitment services including all the necessary informational tools and devices as well as direct to consumer tactics and the appropriate digital options.
Praxis Communications, Inc., headquartered in Brentwood, Tenn., provides the pharmaceutical and biotech industries with a wide range of global services for patient recruitment and retention for clinical trials including patient profiling, recruitment planning, centralized fulfillment, media relations, advertising, and program management. For more information, call Praxis at (615) 312-8207 or visit
www.GoPraxis.com
.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.